Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Sarcoma 1Dermatologic 1

Conditions

Pancreatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 36Urinary Bladder Neoplasms 33Neoplasm Metastasis 20Lung Neoplasms 20Ovarian Neoplasms 19Lymphoma, Large B-Cell, Diffuse 18Cholangiocarcinoma 15Neoplasms 14Nasopharyngeal Carcinoma 14Biliary Tract Neoplasms 14Triple Negative Breast Neoplasms 13Colorectal Neoplasms 12Breast Neoplasms 12Carcinoma, Transitional Cell 11Fallopian Tube Neoplasms 10Recurrence 9Non-Muscle Invasive Bladder Neoplasms 9Gallbladder Neoplasms 8Sarcoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Bile Duct Neoplasms 6Uterine Cervical Neoplasms 5Osteosarcoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Hodgkin Disease 5Endometrial Neoplasms 5Melanoma 4Gastrointestinal Neoplasms 4

Interventions

pembrolizumab 4enfortumab vedotin 3Gemcitabine 3Cisplatin 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1testosterone 17 beta-cypionate 1temsirolimus 1galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20 1dodecyl maltoside 1Valproic Acid 1Testosterone Propionate 1Sunitinib 1Standard of Care 1Sirolimus 1Ringer's acetate 1Radiation Dose Hypofractionation 1Psychiatric Nursing 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Mitomycin 1Methyltestosterone 1Immunoglobulin G 1Fluorouracil 1Etoposide 1Doxycycline 1Disulfides 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urologic Neoplasms × Gemcitabine × 90 days × Clear all
NCT03093909 2026-05-20

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

M.D. Anderson Cancer Center

Phase 1 Recruiting
44 enrolled
DermatologicGenitourinarySarcoma

Bone Neoplasms, Melanoma, Osteosarcoma, Urologic Neoplasms

NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡